Overview

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Status:
Completed
Trial end date:
2020-07-22
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim